Company

About

Ipsum Diagnostics

Ipsum Diagnostics

Atlanta, Georgia, United States

Ipsum Diagnostics is a nationally acclaimed molecular diagnostics laboratory, renowned for its expertise in identifying infectious disease pathogens and antibiotic resistance genes. Our molecular panels leverage the power of polymerase chain reaction (PCR) technology and provide fast results for more effective treatment that leads to improved patient outcomes. Located in Atlanta, GA, our state-of-the-art laboratory specializes in molecular and anatomical pathology. We accommodate workflow needs by providing services such as customized reports, statistical analysis of patients with different treatment plans, and meaningful data to assess overall treatment performance amongst patient populations. Our comprehensive and succinct patient reports can be made available via EMR integration, portal access, fax, or our easy to use mobile or tablet app. Ipsum's software capabilities allow for a superior customized experience, with the highest quality standards that will have your reports completed promptly and efficiently. Ipsum Diagnostics creates a true partnership environment between Provider, Patient, and Laboratory. For locations needing a UPS pickup please follow the below instructions: 1. Call (800) PICKUPS 2. When prompted reply "Schedule a pick"​ 3. You will be asked for your phone number 4. Be prepared to have tracking number ready to provide 5. Provide address of pick up with a time frame UPS Phone Center Shortcuts: https://www.ups.com/us/en/contact/ivr-Popup.page?

Metaclipse Therapeutics

Metaclipse Therapeutics

Atlanta, Georgia, United States

Metaclipse Therapeutics is a preclinical stage biotech company developing novel cancer therapies that are tailored to each patient and their specific tumor. The Company’s first ‘personalized’ cancer therapy is for triple negative metastatic breast cancer. Metaclipse intends to commercialize its products through licensing agreements with major pharmaceutical companies after establishing their safety and effectiveness in early clinical trials by year-end 2019.